Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Diwakar Davar"'
Autor:
Jennifer Bordeaux, Dustin McCurry, Arivarasan Karunamurthy, Lisa H. Butterfield, Rogerio I. Neves, Anil Pahuja, Matthew P. Holtzman, Beiru Chen, Jehovana Orozco Bender, Ahmad A. Tarhini, Yan Zang, Ju Young Kim, John M. Kirkwood, Yan Lin, Cindy Sander, Joseph J. Skitzki, IlaSri B. Summit, Marc S. Ernstoff, Christian Laing, Joseph J. Drabick, Yana G. Najjar, Huang Lin, Jennifer Tsau, Ghanashyam Sarikonda, Igor Puzanov, Hassane M. Zarour, Zeni Alfonso, Amy Rose, James F. Pingpank, Diwakar Davar
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 15
Purpose:Neoadjuvant immunotherapy may improve the clinical outcome of regionally advanced operable melanoma and allows for rapid clinical and pathologic assessment of response. We examined neoadjuvant pembrolizumab and high-dose IFNα-2b (HDI) therap
Autor:
Diwakar Davar, Saro Sarkisian
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 12, Pp 2553-2565 (2018)
Drug Design, Development and Therapy
Drug Design, Development and Therapy
Saro Sarkisian,1 Diwakar Davar2 1Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, USA; 2Division of Hematology-Oncology, Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA, USA Abstract: Melanoma is inc
Publikováno v:
Methods in Molecular Biology ISBN: 9781627037266
Methods Mol Biol
Methods Mol Biol
Melanoma is the third most common skin cancer but accounts for the majority of skin cancer-related mortality. The rapidly rising incidence and younger age at diagnosis has made melanoma a leading cause of lost productive years of life and has increas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ae0766488eb2a8f43e37b69cdf80d4a
https://doi.org/10.1007/978-1-62703-727-3_4
https://doi.org/10.1007/978-1-62703-727-3_4
Autor:
John M. Kirkwood, Diwakar Davar
Publikováno v:
Expert Opin Investig Drugs
INTRODUCTION: Therapies targeting immune checkpoints (CTLA-4) and the MAP kinase signaling pathway (RAS/RAF/MEK/ERK) have transformed the treatment of advanced melanoma in the past year. Agents aimed at other therapeutic targets of interest are being